The FDA granted approval to Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting, according to a press release issued by Novartis.
According to Dr. Maggass, Pluvicto is a breakthrough therapy for patients with metastatic prostate cancer which no longer responds to hormone therapy and has failed chemotherapy. It is a targeted form of precision radio therapy where a protein carrying a radioactive molecule of LU 177 attaches itself to approaching on the prostate cancer cells surface. This delivers a concentrated form of radiotherapy directly to the cancer cells no matter where they are in the body. The results of the vision trial which led to approval of this agent are very exciting.
Pluvicto is available to patients at our Gilbert & Deer Valley locations. Please feel free to reach out to our AZCCC Gilbert or Deer Valley at 480-278-8300 for further information or if you have a patient that may benefit from this treatment.
Arizona Center for Cancer Care provides multi-specialty treatment to more than 30,000 cancer patients across the Valley and understands the importance of serving the entire family. Arizona Center for Cancer Care’s mission is to provide the highest quality cancer treatment in Arizona. At AZCCC, patients can depend on the very best doctors and staffs for cancer care. AZCCC is a cancer center without walls with services stretching across the Valley and beyond.
Arizona Center for Cancer Care is here for you and for your family. For more info please go to https://arizonaccc.com/contact-us/